Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Open-label, Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident (Cohort A) and Recurrent (Cohort B) Patients With Immunoglobulin A Nephropathy

NCT04663204 is registered in ClinicalTrials.gov with University of Leicester as lead sponsor.

NCT NCT04663204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04663204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Open-label, Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident (Cohort A) and Recurrent (Cohort B) Patients With Immunoglobulin A Nephropathy
Lead sponsor
University of Leicester
Phase
Phase 2
Overall status
Recruiting
Start date
December 10, 2020
Completion date
December 31, 2027
Enrollment
24 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, glomerulonephritis, glomerulonephritis, iga, immune system diseases, immunoglobulin a nephropathy, kidney diseases